Ironwood Pharmaceuticals Director Bryan Roberts Unloads 55,450 Shares (IRWD)
Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Bryan Roberts unloaded 55,450 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $12.01, for a total transaction of $665,954.50. The sale was disclosed in a filing with the SEC, which is available at this link.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 0.87% during mid-day trading on Tuesday, hitting $11.43. The stock had a trading volume of 895,948 shares. Ironwood Pharmaceuticals has a 52 week low of $8.95 and a 52 week high of $19.67. The stock’s 50-day moving average is $11.24 and its 200-day moving average is $11.20. The company’s market cap is $1.380 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Tuesday, October 22nd. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was down 94.9% on a year-over-year basis. Analysts expect that Ironwood Pharmaceuticals will post $-2.42 EPS for the current fiscal year.
A number of research firms have recently commented on IRWD. Analysts at Jefferies Group cut their price target on shares of Ironwood Pharmaceuticals from $12.00 to $11.00 in a research note to investors on Thursday, October 24th. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Thursday, October 24th. They now have a $12.00 price target on the stock. Finally, analysts at Cowen and Company upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, October 24th. They now have a $14.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.59.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.